Refine Search
(5)
(6)
(6)
(6)

Metabolic Disorder

In spite of the introduction of several successful drugs in the market, the quest for novel classes of drugs, which are safer and more effective, continues. This is evident from the large number of drugs under development for the treatment of metabolic disorders, which consists of 1,834 active pipeline drugs.

Type 2 Diabetes - Pipeline Review, H1 2018

  • $2,500
  • May 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Type 2 Diabetes - Pipeline Review, H1 2018’, provides an overview of the Type 2 Diabetes pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Type 2 Diabete...

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018

  • $2,500
  • May 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018’, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) pipeline landscape.

The report provides comprehensive information on the therapeut...

Obesity - Pipeline Review, H1 2018

  • $2,500
  • May 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Obesity - Pipeline Review, H1 2018’, provides an overview of the Obesity pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Obesity, complete with analysi...

Hypercholesterolemia - Pipeline Review, H1 2018

  • $2,000
  • May 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Hypercholesterolemia - Pipeline Review, H1 2018’, provides an overview of the Hypercholesterolemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hype...

Osteoporosis - Pipeline Review, H1 2018

  • $2,000
  • April 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Osteoporosis - Pipeline Review, H1 2018’, provides an overview of the Osteoporosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteoporosis, comple...

Dyslipidemia - Pipeline Review, H1 2018

  • $2,000
  • February 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Dyslipidemia - Pipeline Review, H1 2018’, provides an overview of the Dyslipidemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dyslipidemia, comple...